Stem Cell Therapeutics Announces Issuance of Patents in India
News Jul 16, 2009
Stem Cell Therapeutics Corp. has been issued two patents in India: Indian Patent No. 229684 entitled, "Combined Regulation of Neural Cell Production" and Indian Patent No. 229924 entitled, "A Composition for Increasing Neural Stem Cell Number and In Vitro Method of Using the Same".
Together, these patents cover pharmaceutical compositions for increasing neural stem cell number or for producing specialized neural stem cell progeny, with the compositions comprising prolactin in combination with other neural stem cell proliferating agents or differentiating agents, such as erythropoietin ("EPO").
Methods for using prolactin and other such agents in neural stem cell culture are also covered, with the resulting cells being useful, for example, in regenerative transplant therapy.
Dr. Alan Moore, President and CEO, commented as follows: "Overall, India is playing a valuable role in our development programs. It is therefore increasingly important to address intellectual property issues in India. These two patents are part of that process."
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.